Search for a trial

Selecting Ovarian Cancer patients for PARP Inhibitor (SOPI) study

The main objective of the SOPI study is to select the HRD test that best predicts longest PFS on PARP-i in non-BRCA1/2 EOC patients, in order to adequately select patients that will benefit from a PARP-i. Secondary objectives are: to…

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples in a first line setting from patients diagnosed with metastatic Colorectal Cancer (mCRC) to determine the KRAS G12C mutation status as part of the inclusion criteria into the Amgen Phase III clinical trial (Protocol No 20210081) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…